Kurser indlæses...

Prognose

Køb	2
Behold	0
Sælg	0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

Nyheder Til nyhedsfeedet

Sinovac extends deadline for special dividend to June 30, 2026

Sinovac has extended the deadline for submitting payment instructions for the announced special cash dividend of $55.00 per common share to June 30, 2026. Eligible shareholders are those registered at the close of trading on May 23, 2025; the original deadline was December 31, 2025. The company, which typically does not pay dividends, shows weak financial condition with a current market capitalization of about $41.15 million; D.F. King & Co. has been named as the information agent. » Mere på de.investing.com
Sinovac Biotech renews board committees and adjusts governance

After a board meeting, Sinovac Biotech reappointed members to its committees and amended the audit committee’s charter. Simon Anderson and Yuk Lam Lo were appointed to the audit committee, with Anderson as chair; the minimum number of members was reduced from three to two. Andrew Yan, Shan Fu and Yuk Lam Lo make up the remuneration committee, with Lo as chair; the nomination and governance committee consists of Andrew Yan, Yumin Qiu and Yu Wang, with Yan as chair. A legal committee was also established to review claims in certain court proceedings, comprising Andrew Yan (chair) and Yuk Lam Lo. As a foreign private issuer, the company follows the rules of its home jurisdiction, which permits the reduction in audit committee membership. » Mere på de.investing.com
Sinovac receives conditional approval to remain on NASDAQ

The Chinese vaccine maker Sinovac has received conditional approval from the Nasdaq Hearings Panel to remain listed. Sinovac must submit its 2024 annual report (Form 20-F) and interim reports for Q2 2025 (Form 6-K) by May 11, 2026, or face possible delisting. The company appointed Zhonghua Certified Public Accountants for the audit on January 4 and says it will complete the required filings on time. Financial data show weak liquidity (current ratio 0.02) and diluted EPS of -0.03; market capitalization is USD 38.95 million and the share price is USD 0.12. » Mere på de.investing.com
Antigua court affirms Sinovac board until 2026 trial

The High Court of Antigua ordered that Sinovac’s current eight-member board remain in office until a court hearing scheduled for late April/early May 2026. The move follows petitions by several shareholders after a contested extraordinary general meeting and comes at a time when Sinovac’s financial position is rated weak by InvestingPro. The board aims to push for the resumption of NASDAQ trading, complete the audit with new auditors, and appeal a delisting notice. Investors should watch the company’s financial challenges, dividend claims from independent shareholders, and the upcoming court case. » Mere på de.investing.com
Sinovac faces delisting from NASDAQ after late filing of annual report

Sinovac received a delisting notice from NASDAQ because the 2024 annual report was not filed by the extended deadline of November 11. The securities would be suspended at the open of trading on November 21 and removed from the exchange unless the company requests a hearing by November 19; Sinovac said it would contest the move and seek an extension. In response, Sinovac appointed UHY LLP as its new auditor and is working to finalize the filings, but with only $38.1 million in market capitalization, a share price of $0.10 and weak metrics it is under considerable pressure. » Mere på de.investing.com

Historisk udbytte Udbytte

Alle nøgletal for udbytte Alle nøgletal

I 2025 har Sinovac Biotech allerede udloddet 46,86 € i udbytte. Den seneste udlodning fandt sted i juli 2025.

Virksomhedstal

I det seneste år havde Sinovac Biotech en omsætning på 329,01 mio. € og et nettoresultat på -50,87 mio. €

(EUR)	2025	YoY
Omsætning	329,01 mio.	5,26 %
Bruttofortjeneste	223,29 mio.	5,29 %
Nettoresultat	-50,87 mio.	158,23 %
EBITDA	-159,94 mio.	54,98 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	421,77 mio. €
Antal aktier	71,86 mio.
Højeste/laveste i 52 uger	5,87 € - 5,87 €
Udbytte	Nej
Beta	0,00
P/E (PE Ratio)	-7,80
PEG (PEG Ratio)	-0,08
K/I (PB Ratio)	0,10
P/S (PS Ratio)	1,20

Virksomhedsprofil

Sinovac Biotech Ltd. er en biofarmaceutisk virksomhed, der fokuserer på forskning, udvikling, fremstilling og kommercialisering af vacciner mod infektionssygdomme hos mennesker i Folkerepublikken Kina. Virksomhedens produktportefølje omfatter vacciner mod hepatitis A og B; hånd-, fod- og mundsygdom forårsaget af enterovirus 71 (EV71); sæsonbestemt influenza; H5N1- og H1N1-pandemisk influenza; coronavirus; skoldkopper; og fåresyge. De markedsførte produkter omfatter Healive, en inaktiveret hepatitis A-vaccine; Bilive, en kombineret inaktiveret hepatitis A- og B-vaccine; Anflu, en split virion-influenzavaccine; Panflu, en vaccine mod H5N1-influenzavirus; Panflu.1, en vaccine mod influenza A H1N1-virus; en fåresygevaccine til behandling af virussygdom hos mennesker; split virion pandemisk influenzavaccine; og Inlive, en EV71-vaccine. Virksomheden tilbyder desuden skoldkopper, en vaccine til behandling af smitsom infektionssygdom; pneumokok-polysaccharidvaccine, en vaccine til forebyggelse af infektioner med Streptococcus pneumoniae, såsom lungebetændelse og sepsis; kvadrivalent influenzavaccine, en vaccine til beskyttelse mod to influenza A-virus og to influenza B-virus; og CoronaVac, en vaccine mod COVID-19. Derudover omfatter virksomhedens pipeline-produkter sabin inaktiveret poliovaccine, en vaccine til behandling af poliomyelitis, som har gennemført fase III-klinisk forsøg; og røde hunde-vaccine. Virksomheden har samarbejdsaftaler med GlaxoSmithKline Biologicals SA om udvikling af kombinationsvacciner indeholdende mæslinger til det kinesiske marked; Tianjin CanSino Biotechnology Inc. om udvikling af en pneumokokvaccine; og Instituto Butantan om at fremme de kliniske forsøg med CoronaVac, en inaktiveret vaccinekandidat mod COVID-19, til fase III. Sinovac Biotech Ltd. blev grundlagt i 1993 og har hovedkontor i Beijing, Folkerepublikken Kina.